A novel PI3K inhibitor iMDK suppresses non-small cell lung Cancer cooperatively with A MEK inhibitor

Naomasa Ishida, Takuya Fukazawa, Yutaka Maeda, Tomoki Yamatsuji, Katsuya Kato, Kenichi Matsumoto, Tsuyoshi Shimo, Nagio Takigawa, Jeffrey A. Whitsett, Yoshio Naomoto

Research output: Contribution to journalArticle

6 Citations (Scopus)

Abstract

The PI3K-AKT pathway is expected to be a therapeutic target for non-small cell lung cancer (NSCLC) treatment. We previously reported that a novel PI3K inhibitor iMDK suppressed NSCLC cells in vitro and in vivo without harming normal cells and mice. Unexpectedly, iMDK activated the MAPK pathway, including ERK, in the NSCLC cells. Since iMDK did not eradicate such NSCLC cells completely, it is possible that the activated MAPK pathway confers resistance to the NSCLC cells against cell death induced by iMDK. In the present study, we assessed whether suppressing of iMDK-mediated activation of the MAPK pathway would enhance anti-tumorigenic activity of iMDK. PD0325901, a MAPK inhibitor, suppressed the MAPK pathway induced by iMDK and cooperatively inhibited cell viability and colony formation of NSCLC cells by inducing apoptosis in vitro. HUVEC tube formation, representing angiogenic processes in vitro, was also cooperatively inhibited by the combinatorial treatment of iMDK and PD0325901. The combinatorial treatment of iMDK with PD0325901 cooperatively suppressed tumor growth and tumor-associated angiogenesis in a lung cancer xenograft model in vivo. Here, we demonstrate a novel treatment strategy using iMDK and PD0325901 to eradicate NSCLC.

Original languageEnglish
Pages (from-to)197-206
Number of pages10
JournalExperimental Cell Research
Volume335
Issue number2
DOIs
Publication statusPublished - Jul 15 2015

Fingerprint

Mitogen-Activated Protein Kinase Kinases
Phosphatidylinositol 3-Kinases
Non-Small Cell Lung Carcinoma
MAP Kinase Signaling System
Heterografts
Lung Neoplasms
Neoplasms
Cell Survival
Cell Death
Apoptosis
PD 0325901
Growth
In Vitro Techniques

Keywords

  • MEK
  • NSCLC
  • PI3K

ASJC Scopus subject areas

  • Cell Biology

Cite this

Ishida, N., Fukazawa, T., Maeda, Y., Yamatsuji, T., Kato, K., Matsumoto, K., ... Naomoto, Y. (2015). A novel PI3K inhibitor iMDK suppresses non-small cell lung Cancer cooperatively with A MEK inhibitor. Experimental Cell Research, 335(2), 197-206. https://doi.org/10.1016/j.yexcr.2015.03.019

A novel PI3K inhibitor iMDK suppresses non-small cell lung Cancer cooperatively with A MEK inhibitor. / Ishida, Naomasa; Fukazawa, Takuya; Maeda, Yutaka; Yamatsuji, Tomoki; Kato, Katsuya; Matsumoto, Kenichi; Shimo, Tsuyoshi; Takigawa, Nagio; Whitsett, Jeffrey A.; Naomoto, Yoshio.

In: Experimental Cell Research, Vol. 335, No. 2, 15.07.2015, p. 197-206.

Research output: Contribution to journalArticle

Ishida, N, Fukazawa, T, Maeda, Y, Yamatsuji, T, Kato, K, Matsumoto, K, Shimo, T, Takigawa, N, Whitsett, JA & Naomoto, Y 2015, 'A novel PI3K inhibitor iMDK suppresses non-small cell lung Cancer cooperatively with A MEK inhibitor', Experimental Cell Research, vol. 335, no. 2, pp. 197-206. https://doi.org/10.1016/j.yexcr.2015.03.019
Ishida, Naomasa ; Fukazawa, Takuya ; Maeda, Yutaka ; Yamatsuji, Tomoki ; Kato, Katsuya ; Matsumoto, Kenichi ; Shimo, Tsuyoshi ; Takigawa, Nagio ; Whitsett, Jeffrey A. ; Naomoto, Yoshio. / A novel PI3K inhibitor iMDK suppresses non-small cell lung Cancer cooperatively with A MEK inhibitor. In: Experimental Cell Research. 2015 ; Vol. 335, No. 2. pp. 197-206.
@article{f248a7856cc143cfb913d6121b46a8c7,
title = "A novel PI3K inhibitor iMDK suppresses non-small cell lung Cancer cooperatively with A MEK inhibitor",
abstract = "The PI3K-AKT pathway is expected to be a therapeutic target for non-small cell lung cancer (NSCLC) treatment. We previously reported that a novel PI3K inhibitor iMDK suppressed NSCLC cells in vitro and in vivo without harming normal cells and mice. Unexpectedly, iMDK activated the MAPK pathway, including ERK, in the NSCLC cells. Since iMDK did not eradicate such NSCLC cells completely, it is possible that the activated MAPK pathway confers resistance to the NSCLC cells against cell death induced by iMDK. In the present study, we assessed whether suppressing of iMDK-mediated activation of the MAPK pathway would enhance anti-tumorigenic activity of iMDK. PD0325901, a MAPK inhibitor, suppressed the MAPK pathway induced by iMDK and cooperatively inhibited cell viability and colony formation of NSCLC cells by inducing apoptosis in vitro. HUVEC tube formation, representing angiogenic processes in vitro, was also cooperatively inhibited by the combinatorial treatment of iMDK and PD0325901. The combinatorial treatment of iMDK with PD0325901 cooperatively suppressed tumor growth and tumor-associated angiogenesis in a lung cancer xenograft model in vivo. Here, we demonstrate a novel treatment strategy using iMDK and PD0325901 to eradicate NSCLC.",
keywords = "MEK, NSCLC, PI3K",
author = "Naomasa Ishida and Takuya Fukazawa and Yutaka Maeda and Tomoki Yamatsuji and Katsuya Kato and Kenichi Matsumoto and Tsuyoshi Shimo and Nagio Takigawa and Whitsett, {Jeffrey A.} and Yoshio Naomoto",
year = "2015",
month = "7",
day = "15",
doi = "10.1016/j.yexcr.2015.03.019",
language = "English",
volume = "335",
pages = "197--206",
journal = "Experimental Cell Research",
issn = "0014-4827",
publisher = "Academic Press Inc.",
number = "2",

}

TY - JOUR

T1 - A novel PI3K inhibitor iMDK suppresses non-small cell lung Cancer cooperatively with A MEK inhibitor

AU - Ishida, Naomasa

AU - Fukazawa, Takuya

AU - Maeda, Yutaka

AU - Yamatsuji, Tomoki

AU - Kato, Katsuya

AU - Matsumoto, Kenichi

AU - Shimo, Tsuyoshi

AU - Takigawa, Nagio

AU - Whitsett, Jeffrey A.

AU - Naomoto, Yoshio

PY - 2015/7/15

Y1 - 2015/7/15

N2 - The PI3K-AKT pathway is expected to be a therapeutic target for non-small cell lung cancer (NSCLC) treatment. We previously reported that a novel PI3K inhibitor iMDK suppressed NSCLC cells in vitro and in vivo without harming normal cells and mice. Unexpectedly, iMDK activated the MAPK pathway, including ERK, in the NSCLC cells. Since iMDK did not eradicate such NSCLC cells completely, it is possible that the activated MAPK pathway confers resistance to the NSCLC cells against cell death induced by iMDK. In the present study, we assessed whether suppressing of iMDK-mediated activation of the MAPK pathway would enhance anti-tumorigenic activity of iMDK. PD0325901, a MAPK inhibitor, suppressed the MAPK pathway induced by iMDK and cooperatively inhibited cell viability and colony formation of NSCLC cells by inducing apoptosis in vitro. HUVEC tube formation, representing angiogenic processes in vitro, was also cooperatively inhibited by the combinatorial treatment of iMDK and PD0325901. The combinatorial treatment of iMDK with PD0325901 cooperatively suppressed tumor growth and tumor-associated angiogenesis in a lung cancer xenograft model in vivo. Here, we demonstrate a novel treatment strategy using iMDK and PD0325901 to eradicate NSCLC.

AB - The PI3K-AKT pathway is expected to be a therapeutic target for non-small cell lung cancer (NSCLC) treatment. We previously reported that a novel PI3K inhibitor iMDK suppressed NSCLC cells in vitro and in vivo without harming normal cells and mice. Unexpectedly, iMDK activated the MAPK pathway, including ERK, in the NSCLC cells. Since iMDK did not eradicate such NSCLC cells completely, it is possible that the activated MAPK pathway confers resistance to the NSCLC cells against cell death induced by iMDK. In the present study, we assessed whether suppressing of iMDK-mediated activation of the MAPK pathway would enhance anti-tumorigenic activity of iMDK. PD0325901, a MAPK inhibitor, suppressed the MAPK pathway induced by iMDK and cooperatively inhibited cell viability and colony formation of NSCLC cells by inducing apoptosis in vitro. HUVEC tube formation, representing angiogenic processes in vitro, was also cooperatively inhibited by the combinatorial treatment of iMDK and PD0325901. The combinatorial treatment of iMDK with PD0325901 cooperatively suppressed tumor growth and tumor-associated angiogenesis in a lung cancer xenograft model in vivo. Here, we demonstrate a novel treatment strategy using iMDK and PD0325901 to eradicate NSCLC.

KW - MEK

KW - NSCLC

KW - PI3K

UR - http://www.scopus.com/inward/record.url?scp=84937641742&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84937641742&partnerID=8YFLogxK

U2 - 10.1016/j.yexcr.2015.03.019

DO - 10.1016/j.yexcr.2015.03.019

M3 - Article

VL - 335

SP - 197

EP - 206

JO - Experimental Cell Research

JF - Experimental Cell Research

SN - 0014-4827

IS - 2

ER -